Back HCV Treatment

HCV Treatment

EASL 2015: Grazoprevir/ Elbasvir Effective for Treatment-Experienced and HIV/HCV Coinfected Patients

The combination of grazoprevir and elbasvir without ribavirin is highly effective in curing hepatitis C virus infection in 12 weeks in some groups of treatment-experienced patients and in HIV/HCV coinfected people, and a 16-week course of treatment with ribavirin was highly effective even for the hardest-to-treat groups of treatment-experienced patients, according to 2 studies presented last week at the European Association for the Study of the Liver (EASL) 50th International Liver Congress this week in Vienna.

alt

Read more:

EASL 2015: Sofosbuvir + Interferon/Ribavirin Effective for Hard-to-Treat Genotype 3 HCV Patients

A throwback regimen of sofosbuvir (Sovaldi), ribavirin, and pegylated interferon taken for 12 weeks cured 93% of patients with hepatitis C virus (HCV) genotype 3 -- substantially more than sofosbuvir plus ribavirin alone taken for 16 or 24 weeks, according to results from the BOSON study presented Saturday at the European Association for the Study of the Liver (EASL) 50th International Liver Congress in Vienna. Interferon-containing therapy for 3 months was described as "surprisingly well-tolerated."

alt

Read more:

EASL 2015: New European Guidelines Prioritize Interferon-Free Hepatitis C Treatment

The European Association for the Study of the Liver (EASL) released its latest hepatitis C treatment guidelines at the 50th International Liver Congress taking place this week in Vienna. The guidelines recommend a variety of interferon-free direct-acting antiviral (DAA) regimens for people with hepatitis C virus genotypes 1-6. The panel offered recommendations for patient groups that remain difficult to treat, such as those with decompensated cirrhosis, but noted that more research is still needed in several areas. Also concurrent with the conference, EASL and the Latin American Association for the Study of the Liver released joint guidelines for non-invasive assessment of liver disease severity, noting that liver stiffness measurement is becoming the standard of care. 

alt

Read more:

EASL 2015: Sofosbuvir + Daclatasvir + Ribavirin Cures Advanced Cirrhosis and Liver Transplant Patients

An interferon-free regimen of sofosbuvir, daclatasvir, and ribavirin for 12 weeks produced sustained response rates of 83% for hepatitis C patients with advanced liver cirrhosis and 94% for liver transplant recipients, with similar cure rates for those with hard-to-treat HCV genotype 3, according to findings from the ALLY-1 study presented at a late-breaker session at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna. More than half of patients with the most severe decompensated cirrhosis achieved sustained response.

alt

Read more:

EASL 2015: Sofosbuvir/ Ledipasvir + Ribavirin Cures Most Hepatitis C Patients with Advanced Liver Disease

An oral regimen of sofosbuvir/ledipasvir (Harvoni) and ribavirin taken for 12 or 24 weeks produced sustained virological response rates of 85%-88% for genotype 1 hepatitis C patients with decompensated cirrhosis and 95%-98% for liver transplant recipients with less advanced liver damage, according to preliminary results from the SOLAR-2 study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress taking place this week in Vienna.

alt

Read more: